BR112018011663A2 - botulinum toxin for primary mood and affective disorders using neurotransmitter - Google Patents

botulinum toxin for primary mood and affective disorders using neurotransmitter

Info

Publication number
BR112018011663A2
BR112018011663A2 BR112018011663A BR112018011663A BR112018011663A2 BR 112018011663 A2 BR112018011663 A2 BR 112018011663A2 BR 112018011663 A BR112018011663 A BR 112018011663A BR 112018011663 A BR112018011663 A BR 112018011663A BR 112018011663 A2 BR112018011663 A2 BR 112018011663A2
Authority
BR
Brazil
Prior art keywords
neurotransmitter
botulinum toxin
affective disorders
disorders
primary mood
Prior art date
Application number
BR112018011663A
Other languages
Portuguese (pt)
Inventor
Borodic Gary
Acquadro Martin
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/966,759 external-priority patent/US20160095908A1/en
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of BR112018011663A2 publication Critical patent/BR112018011663A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Abstract

a presente invenção refere-se a métodos para tratar distúrbios primários de humor e afetivos, incluindo desordens depressivas, ansiedade e perturbações do sono e distúrbios do snc compreendendo a administração de uma neurotoxina.The present invention relates to methods for treating primary mood and affective disorders including depressive disorders, anxiety and sleep disorders and snc disorders comprising administering a neurotoxin.

BR112018011663A 2015-12-11 2016-12-09 botulinum toxin for primary mood and affective disorders using neurotransmitter BR112018011663A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/966,759 US20160095908A1 (en) 2005-06-14 2015-12-11 Botulinum Toxin for Primary Disorders of Mood and Affect using Neurotransmitter CNS imaging Studies
PCT/US2016/065898 WO2017100624A1 (en) 2015-12-11 2016-12-09 Botulinum toxin for primary disorders of mood and affect using neurotransmitter

Publications (1)

Publication Number Publication Date
BR112018011663A2 true BR112018011663A2 (en) 2018-12-04

Family

ID=59013649

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011663A BR112018011663A2 (en) 2015-12-11 2016-12-09 botulinum toxin for primary mood and affective disorders using neurotransmitter

Country Status (13)

Country Link
EP (1) EP3386538A4 (en)
JP (1) JP2019504824A (en)
KR (1) KR20180093983A (en)
CN (1) CN109069609A (en)
AU (1) AU2016366428A1 (en)
BR (1) BR112018011663A2 (en)
CA (1) CA3007816A1 (en)
CO (1) CO2018007096A2 (en)
IL (1) IL259825A (en)
MX (1) MX2018007105A (en)
RU (1) RU2018125034A (en)
SG (1) SG11201804840SA (en)
WO (1) WO2017100624A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021137667A1 (en) * 2019-12-30 2021-07-08 주식회사 에이티지씨 Composition for treating parkinson's disease containing botulinum neurotoxin, and method for treating parkinson's disease using same
CN114384185A (en) * 2022-01-20 2022-04-22 北京航空航天大学 Application of reagent for detecting gamma-aminobutyric acid content in preparation of kit for diagnosing venous outflow obstruction diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US20070264373A1 (en) * 2004-01-26 2007-11-15 Ian Carroll Toxin Induced Sympathectomy
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
CA2661220A1 (en) * 2006-08-21 2008-02-28 James R. Hauske Multimediator transporter inhibitors for use in treatment of central nervous system disorders
JPWO2010013495A1 (en) * 2008-07-31 2012-01-05 一般財団法人化学及血清療法研究所 Pharmaceutical composition containing highly purified botulinum toxin therapeutic agent as active ingredient and use thereof
US9393291B2 (en) * 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations

Also Published As

Publication number Publication date
MX2018007105A (en) 2018-09-07
AU2016366428A1 (en) 2018-06-28
WO2017100624A1 (en) 2017-06-15
JP2019504824A (en) 2019-02-21
RU2018125034A3 (en) 2020-04-15
CN109069609A (en) 2018-12-21
RU2018125034A (en) 2020-01-13
SG11201804840SA (en) 2018-07-30
IL259825A (en) 2018-07-31
EP3386538A4 (en) 2019-07-17
EP3386538A1 (en) 2018-10-17
CO2018007096A2 (en) 2018-11-22
KR20180093983A (en) 2018-08-22
CA3007816A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
BR112017017286A2 (en) cysteine protease
BR112017017284A2 (en) cysteine protease
BR112018010464A2 (en) topical pharmaceutical formulations to treat related inflammatory conditions
BR112018013065A2 (en) compositions and methods for the treatment of hemoglobinopathies
CO2017005034A2 (en) Recombinant Alkaline Phosphatase Seizure Treatment
BR112018004620A2 (en) kras expression modulators
BR112018070133A2 (en) dispersion, its use and method for photodynamic inactivation of microorganisms
BR112017008938A2 (en) whole-modified protease, expression cassette, composition, household care product, method of regulating protease activity and method of storing a protease in a mixture
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
BR112019006160A2 (en) compositions and methods for treating ophthalmic conditions
ECSP14013152A (en) METALOENZYM INHIBITING COMPOUNDS
BR112017005693A2 (en) method for treating and / or preventing liver disease, and, pharmaceutical composition.
CR20170011A (en) HETEROARILO COMPOUNDS FOR INHIBITION OF CINASA
EA201691872A1 (en) HETEROCYCLIC COMPOUNDS FOR APPLICATION IN THE TREATMENT OF PI3K-GAMMA-MEDIATED DISORDERS
EA201791874A1 (en) FLUORINATED INHIBITORS OF LYZYLOXIDE-LIKE ENZYME-2 AND THEIR APPLICATION
BR112015019995A2 (en) THERAPEUTIC COMBINATION INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR THE TREATMENT OF CANCER
CL2017002242A1 (en) Method to treat a brain tumor
BR112019001039A2 (en) composition for use in the treatment of major depressive disorder
UY36868A (en) COMPOSITIONS FOR TREATMENT OF DISEASES MEDIATED BY INTERLEUQUINE 5 (IL-5)
BR112018003526A2 (en) methods of treating inflammatory diseases
BR112018000776A2 (en) Methods for cancer treatment using apilimod
MX2019002190A (en) Use of pridopidine for treating dystonias.
BR112017025263A2 (en) method for treating neurological disease
BR112017008097A2 (en) method for treating eye conditions
MX2017010654A (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.